alphaVbeta1 integrin: Analyzing the hidden master of fibrosis
αVβ1整合素:分析纤维化的隐藏主宰
基本信息
- 批准号:403724929
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:德国
- 项目类别:Research Fellowships
- 财政年份:2018
- 资助国家:德国
- 起止时间:2017-12-31 至 2020-12-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
We are all depending on efficient wound healing throughout our live. However, a scar remains. While the formation of a scar is important to fully heal wounds, it comes at the prize of lost tissue functionality. For example, scar tissue heals the heart after an infarct, but the scar tissue does not beat, no hair grows on scarred skin, and scars in a lung do not contribute to gas exchange. If the size of the scar exceeds a certain size, it interferes with proper organ function and leads to organ failure. Such a pathogenic progression is called fibrosis. Fibrosis is attributed to more than 40% of all death in the developed world. Obesity is an additional risk factor for fibrosis. With increasing number of obese people it is likely that the number of fibrosis-associated deaths will increase during the next years. Traditionally, fibrosis is named differently for every organ, masking the common features it shares in all tissues. At the onset of fibrosis is the transformation of cells into myofibroblasts that secrete increased amounts of extracellular matrix (ECM) proteins that close the wound and eventually form the scar. The master regulator of this transformation are transforming growth factor beta (TGFbeta) cytokines. TGFbeta is present in the ECM as an inactive LAP-TGFbeta complex. Binding of integrins, important cell-matrix adhesion receptors, to the complex releases TGFbeta. In the past, alphaV-integrins were assumed to be relevant in this process. Recent work suggests, however, that only alphaVbeta1 integrin is responsible for TGFbeta release in physiological settings. Unfortunately, alphaVbeta1 was so far rarely analysed by the research community because of technical challenges. Both parts of the integrin heterodimer associate with many other subunits thereby masking the alphaVbeta1 in the crowd of other integrins. Here, I will establish alphaVbeta1-specific substrates to address this problem by “taking this integrin out of the crowd”. Specifically, I will analyze the ligand preference of alphaVbeta1 to produce binary choice substrates. With this technique, recently established during my PhD, alphaVbeta1 will be physically separated from other integrins due to their differential ligand affinities. By this approach, alphaVbeta1 will be made available for various microscopic and physiological techniques, allowing its in-depth characterization. Using these binary choice substrates with single-particle tracking will give me the unique ability to study dynamics and conformation-specific regulation of alphaVbeta1 in a cellular setting. Moreover, this combination of advanced microscopy and unique substrate functionalization will yield an analysis platform that is suitable for any cell adhesion receptors. By reaching these goals, I will improve the understanding at the same time of alphaVbeta1 and fibrosis. This will offer multiple new possibilities for pharmacological interference with this master regulator of fibrosis.
在我们的生活中,我们都依赖于有效的伤口愈合。然而,伤疤依然存在。虽然疤痕的形成对完全愈合伤口很重要,但它会导致组织功能丧失。例如,疤痕组织在梗塞后愈合心脏,但疤痕组织不跳动,疤痕皮肤上没有毛发生长,并且肺中的疤痕不有助于气体交换。如果疤痕的大小超过一定的大小,它会干扰正常的器官功能并导致器官衰竭。这种致病性进展称为纤维化。在发达国家,超过40%的死亡归因于纤维化。肥胖是纤维化的另一个危险因素。随着肥胖人数的增加,纤维化相关死亡人数可能会在未来几年内增加。传统上,纤维化对每个器官都有不同的命名,掩盖了它在所有组织中共有的共同特征。在纤维化开始时,细胞转化为肌成纤维细胞,肌成纤维细胞分泌增加量的细胞外基质(ECM)蛋白,其闭合伤口并最终形成疤痕。这种转化的主要调节因子是转化生长因子β(TGF β)细胞因子。TGF β作为无活性的LAP-TGF β复合物存在于ECM中。整合素(重要的细胞-基质粘附受体)与复合物的结合释放TGF β。在过去,α V-整联蛋白被认为与该过程相关。然而,最近的研究表明,只有α V β 1整联蛋白负责TGF β在生理环境中的释放。不幸的是,由于技术上的挑战,研究界迄今为止很少对α V β 1进行分析。整联蛋白异二聚体的两个部分都与许多其他亚基结合,从而掩盖了其他整联蛋白群中的α V β 1。在这里,我将建立alphaV β 1特异性底物,通过“将这种整合素从人群中剔除”来解决这个问题。具体来说,我将分析alphaV β 1产生二元选择底物的配体偏好。有了这项技术,最近建立在我的博士学位,alphaV β 1将物理上从其他整合素分离,由于他们的差异配体亲和力。通过这种方法,alphaV β 1将可用于各种显微镜和生理技术,允许其深入表征。使用这些具有单粒子跟踪的二元选择底物将使我能够在细胞环境中研究alphaV β 1的动力学和构象特异性调节。此外,这种先进的显微镜和独特的基底功能化的结合将产生一个适合于任何细胞粘附受体的分析平台。通过实现这些目标,我将同时提高对α V β 1和纤维化的理解。这将为药物干扰纤维化的主要调节因子提供多种新的可能性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dr. Michael Bachmann其他文献
Dr. Michael Bachmann的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Dr. Michael Bachmann', 18)}}的其他基金
Computer simulations of peptide folding, aggregation, and adsorption to solid substrates
肽折叠、聚集和对固体基质的吸附的计算机模拟
- 批准号:
27153304 - 财政年份:2006
- 资助金额:
-- - 项目类别:
Research Fellowships
相似国自然基金
睡眠剥夺经TNN/Integrin α8β1轴调控巨噬细胞极化促动脉粥样硬化的作用及机制研究
- 批准号:2025JJ60778
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
Integrinβ7阳性肥大细胞诱导免疫抑制微环境促进胰腺癌进展机制和干预策略研究
- 批准号:QN25H030033
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
维生素D受体通过抑制Mucin-1/β1-integrin信号通路调节肠道衰老的相关机制研究
- 批准号:MS25H030029
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
低强度脉冲超声波通过调控integrin β1/ FAK/ MAPKs信号轴诱导巨噬细胞自噬治疗糖尿病足的机制研究
- 批准号:
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
Osteopontin-Integrin-TAM-M2轴介导泌乳素细胞腺瘤耐药及机制研究
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
SMYD5 上调 EZH2-integrin β 1 通路促进三阴乳腺癌骨转
移的作用机制及其临床意义
- 批准号:2024JJ6590
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
Fndc5/irisin调控Integrin信号通路在乳腺癌溶骨性骨转移中的作用及
机制研究
- 批准号:
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
丝素蛋白膜拓扑结构通过Integrin-Yap通路诱导BMSCs成软骨分化促
软骨修复的机制研究
- 批准号:
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
β1-integrin经PI3K/AKT通路调控ECM重塑在推拿保护骨骼肌新效应中的机制研究
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:青年科学基金项目
益气除痰方干预COX-2-PGE2/β2 Integrin信号抑制肿瘤相关中性粒细胞促癌极化和黏附的抗肺癌转移机制
- 批准号:82374534
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
相似海外基金
REGULATION OF BONE MARROW MESENCHYMAL STEM CELLS BY VCAM1
VCAM1 对骨髓间充质干细胞的调节
- 批准号:
10537391 - 财政年份:2023
- 资助金额:
-- - 项目类别:
The impact of alcohol-induced ATF6-mediated ER stress and Golgi disorganization on pro-metastatic glycosylation of integrins in prostate cancer
酒精诱导的 ATF6 介导的 ER 应激和高尔基体解体对前列腺癌整合素促转移糖基化的影响
- 批准号:
10826211 - 财政年份:2023
- 资助金额:
-- - 项目类别:
The Role of Bone Sialoprotein in Modulating Periodontal Development and Repair
骨唾液酸蛋白在调节牙周发育和修复中的作用
- 批准号:
10752141 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Surface exosome integrin profiling to predict organotropic metastasis of breast cancer
表面外泌体整合素分析预测乳腺癌的器官转移
- 批准号:
10654221 - 财政年份:2023
- 资助金额:
-- - 项目类别:
VLA-4–targeted 67Cu-LLP2A preconditioning enhances efficacy of T-cell-based adoptive immunotherapy
VLA-4™ 靶向 67Cu-LLP2A 预处理增强基于 T 细胞的过继免疫疗法的疗效
- 批准号:
10713034 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Integrin regulation of vascular function in Alzheimer's disease
整合素对阿尔茨海默病血管功能的调节
- 批准号:
10901016 - 财政年份:2023
- 资助金额:
-- - 项目类别:
CAREER: The molecular interplay between integrin adhesion, allostery and shape-shifting
职业:整合素粘附、变构和变形之间的分子相互作用
- 批准号:
2239492 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Continuing Grant
Treatment of periodontitis by epidermal growth factor receptor inhibitor
表皮生长因子受体抑制剂治疗牙周炎
- 批准号:
479002 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Operating Grants
Regulation of Flt 1 Splicing by Fibronectin and Integrin Signaling During Aging
衰老过程中纤连蛋白和整合素信号传导对 Flt 1 剪接的调节
- 批准号:
10777172 - 财政年份:2023
- 资助金额:
-- - 项目类别:
4D controllable extracellular matrix properties to guide iPSC-derived intestinal organoid fate and form
4D 可控细胞外基质特性指导 iPSC 衍生的肠道类器官的命运和形成
- 批准号:
10644759 - 财政年份:2023
- 资助金额:
-- - 项目类别: